Podcasts about ALK

Jonas Miklovas, Donatas Urbonas ir Lukas Malinauskas „BasketNews.lt podkaste“ svarstė, kas buvo paskutinė vinis, galiausiai privertusi Mindaugą Balčiūną atsistatydinti. Trijulė taip pat aptarė paliktas finansines bėdas ALK, skambučius dėl Rimanto Grigo, kaip keičiasi „Žalgirio“ žaidimas su JV, atsivėrusį Keenaną Evansą, identitetą išlaikiusį „Rytą“ bei didžiausius Eurolygos žaidėjų kontraktus. Tinklalaidės partneriai: Inbank. Atsirado papildomų išlaidų? Su kodu BASKETNEWS gauk nuolaidą vartojimo paskolos sutarties mokesčiui. Feliciana. Itališko įkvėpimo picos su traškia tešla ir gardžiais ingredientais. Išsirink savo mėgstamiausią skonį ir mėgaukis itališka pica namuose! DN Villa. Moderni kaimo turizmo sodyba vestuvėms, jubiliejams, įmonių renginiams ar jaukiam poilsiui gamtos apsuptyje. SPA ir kitos veiklos leis gerai praleisti laiką net ir prastesniu oru. Nealkoholinis alus „Gubernija”. Registracija į BasketNews akademiją. Junkis prie BasketNews Eurolygos Fantasy jau dabar. Temos: Sugrįžus į Lietuvą – oro pavojaus pranešimai (0:00); Donato vizitas Šlovės muziejuje (4:34); Paskutinis lašas, paskatinęs Balčiūną trauktis (6:19); Nesuprantamas Grigo gynimas (10:41); Atmestinas ALK požiūris į Grigo tyrimą (15:09); Kodėl Balčiūnas ignoravo Grigo signalus? (22:56); Skylės, paliktos naujam ALK prezidentui (28:24); Auditas ir kiti galimi ALK kandidatai (35:36); Šansas naujam rinktinės štabui (42:36); Skirtingi „Žalgirio“ veidai su JV ir be jo (53:43); Shaqą išvysime Kaune, ką? (59:46); Atsivėrusio Evanso noras grįžti į elitą (1:03:55); Kas Eurolygoje uždirba daugiausiai? (1:16:10); Rimtas turnyras Vilniuje ir simpatiškas „Rytas“ (1:24:53); Motyvuotam jaunimui – kvietimas į BN akademiją (1:32:55).

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of metastatic non–small cell lung cancer (NSCLC) diagnosis and management for 2026, reflecting the rapidly expanding treatment landscape that is growing to include chemotherapy, immunotherapy, and targeted agents.The discussion began with molecular workup, emphasizing the importance of conducting upfront multigene next-generation sequencing plus PD-L1 testing by immunohistochemistry (IHC) for all nonsquamous disease, with HER2 and c-MET IHC now part of routine evaluation. Drs Armstrong and Tawagi stressed that circulating tumor DNA complements but does not replace tissue biospy, and that a targetable driver generally prompts the initiation of first-line targeted therapy, except in the case of KRAS G12C and NRG1 fusions.Regarding EGFR-mutated disease, they reviewed 3 category 1 first-line options: osimertinib (Tagrisso) monotherapy, osimertinib plus chemotherapy, and amivantamab (Rybrevant) plus lazertinib (Lazcluze), cautioning against overlapping immunotherapy. They detailed post-osimertinib resistance testing and EGFR exon 20 insertions, then addressed ALK, ROS1, BRAF V600E, RET, MET exon 14, NTRK, and NRG1 alterations, noting preferred agents and characteristic toxicities, such as lorlatinib (Lorbrena)–associated hyperlipidemia.Drs Armstrong and Tawagi also covered HER2-directed therapies, including fam-trastuzumab deruxtecan-nxki (Enhertu), as well as antibody-drug conjugates for EGFR-mutated and c-MET–high disease. For driver-negative disease, they stratified first-line therapy by PD-L1 status and histology, discussing immunotherapy monotherapy, chemoimmunotherapy, and dual checkpoint blockade, before reviewing second-line options for patients with or without prior immunotherapy.

Kodėl taip kardinaliai skyrėsi asociacijos „Lietuvos krepšinis“ ir FIBA tyrimų išvados dėl Rimanto Grigo darbo metodų? Apie šį skandalą ir daug kitų temų „BasketNews.lt podkaste“ su Karoliu Tiškevičiumi, Luku Malinausku bei Tomu Purliu. Tinklalaidės partneriai: „Telia Play“. Turi „Telia Play“ – turi viską. Užsisakius norimą Telia Play planą žiūrėk visas LKL rungtynes ir dar daugiau. „Džiugas“ sūrio kamuoliukai. Naujiena – sodraus skonio sūrio kamuoliukai su karštai rūkytomis Kabanossi lazdelėmis. Traškus užkandis, kuriame gausu baltymų, kalcio ir fosforo. Nealkoholinis alus „Gubernija”. Junkis prie BasketNews Eurolygos Fantasy jau dabar.  Temos: Kokį turnyrą savaitgalį laimėjo Purlys? (0:00); Labiausiai stebinanti JV savybė (4:42); Kapitono Ulės spindesys pasirengime (10:21); „Žalgiris“ – be atsarginio penketo (13:22); Nustebinęs Grigonio stogas (16:51); Žaidėjas, per kurį norėtų įdėti M.Jogėla (21:19); Kalniečiui 40: ką prisimename pirmiausia? (22:42); Griežtos FIBA sankcijos Rimantui Grigui (28:39); Krepšininkės palinkėjimas Balčiūnui (33:39); ALK dangstė Grigo istorijas (38:27); Ar tai – didžiausias skandalas istorijoje? (47:28); Karolis debiutavo Žvaigždžių duetuose (57:06); LKL klubų reitinge – „Lietkabelis“ #6? (1:03:30); Jau nekantraujame dėl sezono starto (1:07:08).

Ką byloja Rimo Kurtinaičio spaudos konferencija? Tiesioginėje „BasketNews.lt podkasto“ transliacijoje Karolis Tiškevičius, Jonas Miklovas ir Lukas Malinauskas diskutavo apie tai, kokią Lietuvos rinktinę išvysime kitame PČ lange, pozityvesnę grupės situaciją, dosnų ALK pasiūlymą Songailai bei kurio „Eurolygos Fantasy“ šaukimo vertas JV? Tinklalaidės partneriai: – SENUKAI. Technika namams, darbui ir laisvalaikiui geromis kainomis. Platus vaizdo ir garso technikos, kompiuterių bei stambios ir smulkios buitinės technikos pasirinkimas. Užsukite į fizines parduotuves arba https://www.senukai.lt/ – Nord VPN. Apsilankykite nordvpn.com/basketnews ir dvejų metų planui gaukite keturis papildomus mėnesius. Jei nepatiks - per 30 dienų galite atgauti pinigus. – Nealkoholinis alus „Gubernija”, daugiau informacijos – https://gubernija.lt/ – Junkis prie BasketNews Eurolygos Fantasy jau dabar: https://fantasy.basketnews.lt Temos: Rugsėjo 1-oji – jautresnė nei įprastai (0:00); Karolio linkėjimai Jomantui (4:26); Įtemptai išsaugota šalies viltis (6:59); Pilkosios teisėjų zonos prieš Nurkičių (10:21); Tubelio judesiai šokių aikštelėje (15:31); Bėdos, kurias sprendė Ąžuolas (22:15); Taktinis ėjimas prieš bosnių tritaškius (23:53); Kitokia realybė: ultimatumas bosniui (25:57); Stenionis krypsta ACB link? (31:24); Filmas apie V. Dambrausko istorinį žygį (33:13); Kurtinaičio nenoras paleisti rinktinės (37:08); Ar Songaila priims rinktinės pasiūlymą? (38:54); Billo Petersono džiaugsmas štabe (46:19); Domarkas – neoficialus rinktinės vadovas (48:27); Dekonstruokime Balčiūno argumentus (52:33); Mūsų PČ grupės scenarijai (59:08); Kokį dvyliktuką matysime lapkritį? (1:00:44); Džiaugsmas dėl Ukrainos ir Bagatskio pyktis (1:10:53); Žalias terminatorius JV (1:13:44); Diskusija: ką rinktis Fantasy #2 šaukimu? (1:15:39); BN Live su Mikaičiu – bilietų beveik nėra (1:22:26).  

Norėdami matyti visą podkastą spauskite čia: https://contribee.com/krepsinisnet 00:00 – rugsėjo 1-oji 02:17 – Sarajevo klubas į Europos taurę 03:45 – lietuvių pergalė prieš bosnius 25:38 – ar R.Kurtinaitis liks? 38:50 – kokia rinktinė bus lapkritį 52:24 – graikai ir latviai kritikuoja savus 1:01:04 – „Žalgirio“ ir „Ryto“ draugiškos per TV3 Rėmėjų dalyje aptartos šios temos: 1:05:25 – pirmieji įspūdžiai apie „Žalgirį“ 1:15:00 – ar atsisakę žaidėjai „nepridėjo į kelnes“ 1:16:12 – ar ALK tikisi, kad viskas pasimirš 1:17:55 – kodėl neina į darbą, kai kažko nemėgsta 1:19:33 – sostų karai „Ryte“ 1:23:04 – kas būtų „lange“ kitokioje situacijoje 1:28:20 – teisėjas viešai paskelbė melą 1:32:30 – I.Urbono nuoskauda ir talentai su vaidmeniu „Žalgiryje“ 1:38:46 – ar M.Blaževičiui pakenks dalyvavimas rinktinėje 1:43:49 – koks galėtų būti žaidėjų ribojimas Eurolygoje 1:49:37 – rinktinės sudėtis 2029 m. 1:52:47 – „Jonavos“ realybė 1:56:23 – lietuvių agentai ir latvių ryšys su rusais

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of early-stage and locally advanced non–small cell lung cancer (NSCLC) for 2026, reflecting recent shifts in staging and perioperative therapy.The discussion began with histology, distinguishing adenocarcinoma (positive for TTF-1 and CK7) from squamous cell carcinoma (positive for p63 and p40). Turning to staging, Drs Armstrong and Tawagi emphasized the 9th edition of the lung cancer TNM staging system, noting that T categories are unchanged but N2 is now split into N2a and N2b, and M1c is now split into M1c1 and M1c2. They also stressed the importance of biomarker testing for PD-L1, EGFR, ALK, and RET.Regarding treatment, they explained that stage IA disease warrants surgery or stereotactic body radiation therapy without systemic therapy. In resectable disease that is 4 cm or larger or node-positive disease, driver mutations guide management: osimertinib (Tagrisso) for EGFR-mutated disease, alectinib (Alecensa) for ALK-positive disease, and selpercatinib (Retevmo) for RET-mutated disease, with immunotherapy avoided in EGFR-mutated or ALK-positive tumors. For driver-negative disease, they reviewed 4 category 1 regimens, including neoadjuvant nivolumab (Opdivo) and perioperative pembrolizumab (Keytruda) or nivolumab, cautioning against switching agents in the middle of a treatment course.Drs Armstrong and Tawagi then addressed adjuvant immunotherapy, unresectable stage III disease management with concurrent chemoradiation followed by consolidative durvalumab (Imfinzi) or osimertinib, surgical candidacy, adjuvant chemotherapy regimens, postoperative radiation, and special circumstances, including superior sulcus tumors.

Tarsus Pharmaceuticals announced plans to acquire Alkeus Pharmaceuticals, including its emerging oral treatment for Stargardt disease, gildeuretinol (ALK-001), in a deal valued up to $800 million. Stargardt disease is the most common form of inherited macular degeneration and is often diagnosed in children or teens. There are no current treatments.

Ką parodė Lietuvos rinktinės pasirengimo etapas? Į tai „BasketNews.lt podkaste“ atsakė Jonas Miklovas, Karolis Tiškevičius ir Žygimantas Skučas, kurie taip pat aptarė į PČ atranką be įtampos keliaujančią rinktinę, atviras istorijas iš auksinės kartos laikų, skambiausius Eurolygos klubų vasaros darbus bei istorinius mūsiškių pasiekimus kitose sporto šakose. Projektą finansuoja Medijų rėmimo fondas. Tinklalaidės partneriai: carVertical. Neapsigauk perkant naudotą automobilį, patikrink jo istoriją. Su kodu BASKETNEWS gauk iki 55% nuolaidą ataskaitoms.  BRITE: -25% su kodu BN.  BasketNews Eurolygos Fantasy jau netrukus. Spėk FIBA Pasaulio čempionato atrankų rungtynių rezultatus ir laimėk BasketNews prizus. Temos: Kurią čeburekinę rekomendavo Kurtinaitis? (0:00); Vestuvės be elektros ir audros padariniai (3:51); Kaip derėtų vertinti rinktinę? (9:45); Skersio frazė, išdalinti kvietimai ir pikti fanai (17:13); Turnyro su universitetais nauda ALK (31:02); Tramplinas Stenioniui ir karštas pokalbis rūbinėje (33:56); „Krepšinis Lietuvoje nemiršta…“ (44:44); Išlaisvėjęs Maksvytis grąžino prisiminimus (50:16); Atvirai: lažybininkų pamokos Skučui (56:17); Skučo stebuklas, padėjęs iškopti į U20 finalą (1:02:06); Lietuva – disko metimo šalis (1:08:35); Kurie EL perėjimai intriguoja labiausiai? (1:13:36); Prieš išvyką į Turkiją – žinutė rinktinei (1:33:01). 

Norėdami matyti visą podkastą spauskite čia: https://contribee.com/krepsinisnet 00:00 – J.Lekšas pirmą kartą lankysis Utenos arenoje 04:10 – nupigintas Lietuvos krepšinis 24:10 – ALK kalbasi su vienu treneriu 30:00 – lūžis mače su Mičigano universitetu 48:00 – kas galėtų paimti D.Stenionį 55:35 – laukia turkai Rėmėjų dalyje aptartos šios temos: 1:01:45 – ar TV3 draudžia kritikuoti ALK 1:03:43 – ar nepelnytai pamiršti kiti U16 žaidėjai 1:08:44 – kur riba tarp gandų ir naudos agentams 1:13:25 – ar etiška klausti R.Kurtinaičio apie jo sveikatą 1:14:57 – Ą.Tubelio krūvis ir jo saugojimas 1:17:30 – kodėl D.Doualla dar gauna darbą 1:19:13 – ar šie metai beprotiškiausi Lietuvos krepšinyje 1:21:10 – koks užsienietis galėtų treniruoti rinktinę 1:23:10 – kodėl lietuviai turi problemų su kamuolio driblingu 1:24:58 – kodėl D.Motiejūnas yra nemėgstamas 1:27:05 – T.Okmano indėlis į „Žalgirio“ biudžetą 1:28:51 – kodėl Tautvydas bijo vykti į JAV 1:31:08 – naujo Eurolygos formato įtaka „Žalgirio“ biudžetui 1:33:00 – ar rinktinės populiarumą perima „Žalgiris“ 1:38:24 – kokia prasmė L.Kleizai būti rinktinėje 1:39:45 – solidi vasara LKL klubams 1:44:55 – menedžeris startavo      

00:00 – rinktinės sprigtas nuo estų 32:12 – ALK darbo metodai 43:50 – nudžiugino rezervinė 50:10 – Th.Walkupo elgesys 1:01:51 – artėja sezonas

De danske selskaber fortsætter rækken af opjusteringer - nu også fra Novonesis og GN. Torsdagen byder også på regnskaber fra ALK og Gubra, og Millionærklubben zoomer især ind på medicinalsektoren, der er meget mere end Novo Nordisk. Hvor er det godt at sætte sine penge lige nu? Amerikanske Moderna blev verdenskendt for sin coronavaccine, og nu er selskabet tilbage i overskrifterne med en potentielt vaccine mod modermærkekræft. Det sendte onsdag aktien op med 170 pct. på én dag. I studiet er Lau Svenssen, stifter og chefanalytiker hos Svenssen og Tudborg - og undervejs taler vi bl.a. med ALK-topchef Peter Halling og senioranalytiker i Sydbank Søren Løntoft. Vært: Lasse Ladefoged, journalistisk chef, Euroinvestor (lala@euroinvestor.dk)See omnystudio.com/listener for privacy information.

Prieš „BasketNews.lt podkastą“ paaiškėjo, jog ne visi Lietuvos rinktinės draugiški mačai bus tokie, apie kokius buvo skelbta. Jonas Miklovas, Karolis Tiškevičius ir Lukas Malinauskas aptarė apgautus JAV universitetus bei sirgalius, reputacinę žalą, žaibišką ALK reakciją į Jono Mačiulio pasisakymus, Moterų lygos bėdas ir Latvijoje augantį monstrą. Tinklalaidės partneriai: – Telia Play Mėgaukis kultiniais „Disney+“ serialais bei filmais kartu su „Telia“ – rinkis televiziją ar 5G ryšio planą su įskaičiuotu „Disney+“ ir sutaupyk net 30 %! Daugiau informacijos čia. – Žemaitijos pieno kefyro kokteiliai „Kefyrix". Gaivus, maistingas ir gausus baltymų užkandis. Du išskirtiniai skoniai – „Pasaulio stebuklai" ir „Šakotis". – Spėk FIBA Pasaulio čempionato atrankų rungtynių rezultatus ir laimėk BasketNews prizus čia! Temos: Su kuo prie stalo sėdėjo Karolis? (0:00); Kas dėliojo tokį rinktinės planą? (7:31); ALK reputacijai – dar vienas  niuksas (20:25); Javtoko byla ir Mačiulio prognozė dėl Buzelio (32:50); Su Balčiūnu ALK nariai yra saugūs (38:40); Kurių žaidėjų dar trūksta „Žalgiriui“? (42:47); LKL klubų pasirengimas įsibėgėja (45:19); Centralizacija: miglota ateitis Moterų lygoje (49:52); Ką iš dėdės perėmė D.Jasikevičius? (1:02:28); Kaimynystėje auga tikras monstras (1:08:28); Kokius vaisius vasarą raškė jaunimas? (1:14:10); Nestabdanti Juškaitė kelsis į „Fenerbahce“ (1:18:23).

As part of IASLC's ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with Dr. Tony Mok, Dr. Chao Zhang, and Dr. Wen-Zhao Zhong. The discussion reviews advances in ALK+ non-small cell lung cancer (NSCLC).

Tiesioginėje „BasketNews.lt podkasto“ transliacijoje Jonas Miklovas, Donatas Urbonas ir Lukas Malinauskas diskutavo apie naują rinktinės realybę, lyderių aroganciją, masiškiausią atsisakymų bangą, „Lions“ aprangą apsivilksiantį Keenaną Evansą bei tai, kiek „Rytas“ mokės naujajam komandos puolimo talentui.  Tinklalaidės partneriai: – NordVPN. Apsilankykite nordvpn.com/basketnews ir dvejų metų planui gaukite keturis papildomus mėnesius. Jei nepatiks - per 30 dienų galite atgauti pinigus. – Inbank. Atsirado papildomų išlaidų? Su kodu BASKETNEWS gauk nuolaidą vartojimo paskolos sutarties mokesčiui. Temos: Rinktinėje – skaudi realybė (0:00); Rinktinės retorikoje nepasikeitė niekas (7:05); Kritika procesui, o ne asmenybėms (12:33); Kur ta „geležinė tvarka“? (14:59); Apie ką yra rinktinės vadovo pozicija (22:53); Kodėl Jonas slėpėsi Giminės baliuje (24:39); Klausimai apie Kurtinaičio sveikatą (26:07); Neįvykusio žaidėjų boikoto priežastys (28:40); Pasiteisinimai ir ALK komunikacinė linija (39:12); Sustokim: rinktinės pergalių nori visi (43:55); Koks rezervinės rinktinės tikslas? (47:10); Į Birštoną atvykęs D-Mo kalbėti atsisakė (55:19); Donato idėja kolegoms vienytis (57:07); Kiek „Ryte“ uždirbs žvėriška taškų mašina (1:02:26); Donato gautos žinutės ir Karolis TV projekte (1:11:22); „Žalgirio“ sutartis su Evansu – pamatuota investicija? (1:14:29); Rimta turinio porcija BN+ nariams (1:22:47).

Norėdami matyti visą podkastą spauskite čia: https://contribee.com/krepsinisnet 00:00 – ALK konferencija ir boikotas 30:46 – LeBrono sprendimas 37:35 – daug naujokų Eurolygoje 43:05 – atviras M.Echodo kontraktas 46:01 – „Ryto“ naujokas 50:38 – kitų komandų darbai 59:45 – ASVEL išsprendė problemas Rėmėjų dalyje aptarti šie klausimai: 1:04:48 – du žaidėjai iš Rusijos lygos pas Šarą 1:07:47 – L.Eglinsko pasisakymai ir sąmokslo teorija 1:12:42 – geresnis nei pernai „Lietkabelis“ ir klubo pardavimas 1:18:59 – C.Hendersono alga 1:19:32 – kita Š.Jasikevičiaus stotelė – „Žalgiris“? 1:23:04 – kodėl tiek kalbama apie „Žalgirio“ plačią sudėtį 1:26:23 – T.Okmanas domėjosi „Ryto“ akcijomis 1:29:21 – blic klausimai 1:35:08 – daug prašautų perspektyvių žaidėjų dešimtuke 1:38:45 – kur rinktinės sirgalių grupuotė? 1:40:37 – prasčiausi žaidėjų pasirinkimai rinkoje 1:44:12 – kuo baigsis skandalas NKL 1:49:14 – slovėnų jaunimo atgimimas 1:51:13 – krepsinis.net komanda vadovauja federacijai

This episode reviews new evidence supporting extended DAPT beyond one year for selected patients after multivessel PCI, the role of MRD-guided decisions for maintenance lenalidomide in multiple myeloma, adjuvant ensartinib for resected ALK-positive NSCLC, and emerging data on semaglutide and combination therapy for MASH-related cirrhosis. The studies highlight how precision medicine continues to refine treatment duration, biomarker-driven care, and therapeutic selection across multiple specialties.

How could cellular therapies and cancer vaccines transform the future of treatment for ALK-positive lung cancer? Host Dr. Narjust Florez sits down with Dr. Vincent Lam and Dr. Carmen Mecca to explore the latest research, the science driving these innovative approaches, and what these advances could mean for patients and the future of precision oncology. Key Topics Covered: • ALK-positive lung cancer • Cellular Therapy • Vaccines Guests: Vincent Lam, MD Associate Professor of Oncology, Johns Hopkins University School of Medicine Director, Thoracic Oncology Clinical Research Program Sidney Kimmel Comprehensive Cancer Center Carmen Mecca. PhD Postdoctoral Fellow, Chiarle Lab Department of Pathology Boston Children's Hospital

JCO PO author Dr. Emily Miao at Mass General Brigham Cancer Institute shares insights into the JCO PO article, "Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK-Rearranged Squamous and Adenosquamous Non–Small Cell Lung Cancers." Host Dr. Rafeh Naqash and Dr. Miao discuss the clinicogenomic characteristics and treatment outcomes of patients with ALK+ squamous and adenosquamous lung cancers and how these outcomes compare to those of patients with ALK+ adenocarcinoma treated with first-line alectinib. LINK TO FULL TRANSCRIPT

Send us Fan MailThe July 2026 PBS update brings a number of important changes for oncology clinicians, with several new and expanded cancer medicine listings set to improve access to cancer treatments across breast, lung, blood and biliary tract cancers.In this episode, Rachael Babin and Professor Craig Underhill discuss the clinical significance of the latest Pharmaceutical Benefits Scheme changes, including who is now eligible for treatment, what these listings mean for multidisciplinary care and why comprehensive biomarker testing continues to grow in importance.In this episode:PBS listing for pertuzumab (Perjeta®) in high-risk HER2-positive early breast cancer Listing of alectinib (Alecensa®) for ALK-positive non-small cell lung cancer Osimertinib (Tagrisso®) listing for EGFR-mutated unresectable Stage III NSCLC following chemoradiation First PBS listing of romidepsin (Romidepsin-Reach®) for relapsed peripheral T-cell lymphoma First PBS listing of futibatinib (Lytgobi®) for FGFR2-altered advanced cholangiocarcinoma What the new broad (multi-cancer) PBS listing principles for PD-(L)1 inhibitors could mean for future cancer drug fundingFollow The PBS Update for regular discussions on PBS listings and oncology policy changes affecting Australian healthcare professionals.Visit the Show Notes for links to the PBS updates discussed in this episode and to send us audio feedback or questions for future episodes.Proudly produced by The Oncology Network

Summer Farmen and Jeff Sturm share their personal cancer journeys and the mission behind ALK Positive, CTI's Q3 Charity of the Quarter.ALK Positive is a patient-driven organization dedicated to improving outcomes for individuals living with ALK-positive cancer.Together, they discuss how they became advocates within a global patient community, the importance of genetic testing and second opinions, and the role of research initiatives and clinical trials in advancing treatment options and improving patient outcomes.00:00 Introduction to ALK Positive and today's guests, Summer Farmen and Jeff Sturm. 01:14 Summer and Jeff share their personal cancer journeys and what led them to become advocates within the ALK Positive community. 02:33 The mission of ALK Positive: connecting patients, funding research, and ensuring no one faces the diagnosis alone. 03:49 Why second opinions matter and how specialized expertise can significantly impact treatment decisions.  06:19 Research initiatives supported by ALK Positive, including clinical trials, grants, and collaborations focused on new treatment approaches. 10:46 Challenging the perception of ALK-positive cancer as a “rare” disease and advocating for greater representation in research and clinical trials. 13:22 How targeted therapies have transformed outcomes and extended survival for many ALK-positive patients.15:47 The realities of survivorship: managing side effects, quality of life, and the role of palliative care. 17:27 The importance of genetic testing, monitoring disease progression, and making informed treatment decisions. 21:15 Clinical trial participation: common barriers, improving access, and helping patients connect with opportunities. 26:16 Building community through support groups, education programs, Healing Arts initiatives, and patient connections.  28:46 Addressing the emotional and mental health challenges that often accompany a cancer diagnosis. 32:50 Looking ahead: emerging therapies, vaccine research, precision medicine, and the future of ALK-positive cancer treatment. 36:51 Resources available through ALK Positive and how patients and caregivers can get involved.  37:54 Closing thoughts on advocacy, community, and the patient voices helping shape the future of cancer research.

In this episode, Dr. Paul Wheatley-Price sits down with Dr. Tony Mok, Li Shu Fan Professor in the Department of Clinical Oncology at the Chinese University of Hong Kong, to break down some of the biggest lung cancer highlights from the 2026 ASCO Conference, held in Chicago this June. Together, they discuss new research on targeted treatment after surgery for RET-positive lung cancer, immunotherapy for advanced squamous NSCLC, and a long-term update on first-line targeted therapy for ALK-positive lung cancer. They also look ahead to emerging research coming up in KRAS-mutated lung cancer!

Guest: Urs Weber, MD For patients with ALK-positive non-small cell lung cancer, staying on therapy often means staying ahead of treatment-related toxicities. Join Dr. Urs Weber, Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus, as he explores practical strategies for toxicity management, dose optimization, and shared decision-making to help support durable outcomes.

Guest: Urs Weber, MD As outcomes improve for patients with ALK+ non-small cell lung cancer, attention is shifting toward therapies designed to push disease control even further. Tune in as Dr. Urs Weber examines promising agents in development and discusses the momentum driving the next phase of ALK-targeted treatment. Dr. Weber is an Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus.

Guest: Urs Weber, MD Advances in targeted therapies have dramatically improved outcomes for patients with ALK-positive non-small cell lung cancer, but new resistance challenges continue to emerge. In this episode, Dr. Urs Weber discusses how cancers adapt to treatment, why off-target resistance and histologic transformation are becoming increasingly important, and where future research may help close critical gaps in care. Dr. Weber is an Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus.

This week Nick talks to Alk BrandAlk Brand is a global agribusiness leader and the Chief Executive Officer of Wynnstay Group PLC, one of the UK's leading agricultural supplies businesses. With more than two decades of executive leadership experience, he has led major food, agriculture, and supply chain organisations across five continents, including serving as Global CEO of Westfalia Fruit and Hans Merensky Holdings, Managing Director of Richardson Milling, and CEO of Pioneer Foods UK. Nick and Alk discuss Alk Brand's lifelong connection to agriculture, from growing up on a farm in South Africa to leading major global agribusinesses and becoming CEO of Wynnstay Group. The conversation explores Wynnstay's role in supporting UK food security through its feed, arable, grain trading, and retail operations, as well as the company's growth strategy, investment priorities, and transformation programme, Project Genesis. They discuss the resilience of British farmers, the importance of rural communities, sustainability, innovation, logistics, and technology in modern agriculture, alongside the opportunities for expansion through organic growth and acquisitions. Alk also shares his leadership philosophy, his optimism for the future of UK agriculture, and his belief that Wynnstay can continue to grow by becoming an increasingly integrated and valuable partner to farmers across the UK. Book Choice The Goal by Eliyahu M GoldrattMusic ChoiceAmazing Grace by Aretha Franklin This content is issued by Zeus Capital Limited (“Zeus”) (Incorporated in England & Wales No. 4417845), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (“FCA”) for designated investment business, (Reg No. 224621) and is a member firm of the London Stock Exchange. This content is for information purposes only and neither the information contained, nor the opinions expressed within, constitute or are to be construed as an offer or a solicitation of an offer to buy or sell the securities or other instruments mentioned in it. Zeus shall not be liable for any direct or indirect damages, including lost profits arising in any way from the information contained in this material. This material is for the use of intended recipients only.

ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list: 1. RASolute 302 - daraxonrasib and its standing ovation 2. MajesTEC-9 - 2L teclistamab in multiple myeloma in patient population 100% exposed to CD-38 targeting drugs 3. Initsmeran autogene + pembrolizumab in resected melanoma. Only a Phase 2 study, but super promising and exciting use of personalized medicine using mRNA technology 4. Libretto-043 - adjuvant selpercatinib in RET-fusion positive NSCLC following resection and platinum-based chemotherapy (in most of these patients) 5. PROTEUS - meh 6. SARC041 - Phase study of abemaciclib vs. placebo in dedifferntiated liposarcoma. The placebo did very poorly 7. CROWN at 7-years continues to offer an enticing PFS plateau with lorlatinib use in advanced ALK rearrangement+ NSCLC The Learning Oncology Companion from KelleyCPharmD: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

This episode of the PeerDirect Medical News Podcast reviews three developments with potential implications across nephrology, oncology, and public health. Highlights include the FIND-CKD trial showing finerenone may slow disease progression in chronic kidney disease patients without diabetes, seven-year CROWN trial data demonstrating durable long-term disease control with lorlatinib in advanced ALK-positive lung cancer, and a JAMA Network Open study linking measles-related vitamin A misinformation to increased toxic exposures. Together, these findings underscore evolving treatment paradigms and the growing impact of health communication on patient outcomes.

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences.In this episode, guest host Erin Schenk, MD, PhD, at the University of Colorado Anschutz in Aurora, an associate professor of medicine in the Division of Medical Oncology, sat down with D. Ross Camidge, MD, PhD, to highlight Dr Camidge's storied career and life. Driven by a relentless curiosity that often manifested in him "interrogating" those around him, Camidge chose a career in medicine because of the immediate effect he saw it could have on people's lives.His path included a formative gap year working at McDonald's and serving as a caregiver for a man with cerebral palsy. After studying at Oxford, he faced a significant professional and personal low when pursuing his PhD at Cambridge. Struggling with a difficult project, he persevered by pivoting his research and finding resilience through peers, eventually returning to practicing clinical medicine and finding his calling in oncology due to its unique overlap of molecular biology and opportunities for deep patient connection.Seeking further opportunities, Dr Camidge moved to the United States to lead the lung cancer program at the University of Colorado School of Medicine. He became a pivotal figure in the development of targeted therapies, specifically crizotinib for ALK-positive lung cancer. Beyond drug development, he championed the use of molecular profiling and established a global remote second opinion program.In 2022, Dr Camidge's perspective shifted profoundly following his own lung cancer diagnosis. This experience forced him to evolve from a "questioning machine" into someone more amenable to accepting love and support. He now integrates this dual perspective into his work, emphasizing that oncology must go beyond science to address the human experience of treating real people.

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Isabel Preeshagul from Memorial Sloan-Kettering to discuss the latest advancements in lung cancer presented at ASCO 2026. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We dived into four key studies that could change clinical practice: LIBRETTO-432: exploring the promising event-free survival data with selpercatinib in RET-positive disease and its implications for adjuvant therapy. CROWN 7yr Update: seven-year progression-free survival results with lorlatinib in ALK-positive non-small cell lung cancer and the associated side effects. CHRYSALIS-2: exciting findings regarding amivantamab for atypical EGFR mutations and its potential to become the new standard of care. HARMONi-6: dual-headed drug ivonescimab combined with chemotherapy in metastatic squamous cell lung cancer and its intriguing results. We also touched on the importance of molecular testing for all patients, regardless of stage or histology, and highlighted the latest updates on tarlatamab in small cell lung cancer. Tune in for an insightful discussion that aims to keep our oncology community informed and engaged with the latest research and treatment options! Don't forget to like, subscribe, and check out our other episodes for more insights on oncology treatments, conference highlights, and FDA approvals. #ASCO2026, #LungCancer, #ALKPositive, #RETPositive, #OncologyBrothers

In this Part 1 of 2 ASCO 2026 Highlights episodes, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in ALK-positive disease, emerging data for neladalkib, and promising results for sunvozertinib in EGFR exon 20 insertion–positive NSCLC, highlighting how these findings may influence treatment decisions across disease stages. Guests: Dr. Alice Shaw. is a Professor of Medicine at Harvard Medical School, Chair of Medical Oncology, and a thoracic oncologist at Dana Farber Cancer Institute. She is widely recognized as a pioneer in the field of ALK-positive non-small cell lung cancer, having led landmark clinical trials that established crizotinib, ceritinib, and lorlatinib as standards of care. Dr. Jonathan W. Goldman is a Professor of Medicine and thoracic oncologist at the UCLA David Geffen School of Medicine, where he serves as a principal investigator in the Phase I drug development program. Dr. Goldman has been at the forefront of early-phase oncology trials across multiple tumor types, with a particular focus on novel therapeutics in lung cancer, and he was the presenting author of Libretto 432 at the plenary session at the 2026 ASCO

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the exciting world of metastatic non-small cell lung cancer (NSCLC) with a focus on targeted mutations in the frontline setting. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We were joined by Dr. Eric Singhi from MD Anderson Cancer Center, to discuss the latest advancements in treatment options, including: Common EGFR mutations and the benefits of combination therapies over single-agent osimertinib. The role of CNS involvement in treatment decisions and the importance of patient-centered care. Strategies for managing disease progression and the significance of re-biopsy. Insights into ALK-positive disease, including the efficacy of lorlatinib and alectinib. The latest developments in treating rare mutations like NTRK, MET, RET, and HER2. With a wealth of clinical data and practical insights, this episode is packed with valuable information for oncologists and healthcare professionals. Tune in to learn how to navigate the complexities of NSCLC treatment and improve patient outcomes. Don't forget to subscribe for more discussions on oncology topics and share your thoughts in the comments below! #LungCancer, #TargetedTherapy, #PrecisionMedicine, #NGS, #OncologyBrothers

Medyascope ve İklim Haber işbirliğiyle hazırlanan COP31 Yolu programının bu bölümünde, Dr. Barış Doğru'nun moderatörlüğünde SHURA Enerji Dönüşümü Merkezi Direktörü Alkım Bağ Güllü ile Türkiye'nin enerji dönüşümü ve iklim politikaları ele alınıyor. Programın konuğu Alkım Bağ Güllü, COP31'in Türkiye için taşıdığı fırsatları, fosil yakıtlardan çıkış sürecini ve 2053 net sıfır hedefini değerlendiriyor. Kasım ayında Antalya'da düzenlenecek COP31'in, Türkiye'nin enerji politikaları açısından kritik bir dönüm noktası olabileceği vurgulanıyor. Yenilenebilir enerji yatırımları artsa da, fosil yakıtlardan çıkışa dair net bir yol haritasının eksikliği dikkat çekiyor. Programda ayrıca enerji güvenliği, büyüme ve iklim hedefleri arasındaki denge tartışılıyor. Programda öne çıkan başlıklar:

Sjældent har det danske børsmarked haft så travlt, som det får i disse dage, for det vælter ind med regnskabstal og salgsopdateringer fra nogle af de helt store danske virksomheder i denne uge. Millionærklubben står tirsdag klar til at tage imod med Lau Svenssen i studiet og med kommentarer fra topcheferne hos ISS og ALK. Også Jyske Bank bidrager til analyserne, når senior analytiker Haider Anjum giver sit besyv med om dagens regnskab fra Novonesis. Vært: Bodil Johanne GantzelSee omnystudio.com/listener for privacy information.

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain dive deep into the treatment algorithms for early-stage non-small cell lung cancer (NSCLC) with curative intent. Joined by leading thoracic medical oncologist Dr. Sanjay Popat from London, they discussed the critical role of next-generation sequencing (NGS) in treatment planning, the importance of proper staging, and the implications of actionable mutations. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics covered included: The significance of NGS testing and its impact on treatment decisions. Insights from the CHECKMATE 816 trial, highlighting the benefits of neoadjuvant chemoimmunotherapy. The complexities of post-operative immunotherapy and patient-shared decision-making. The role of adjuvant chemotherapy in patients with actionable mutations like EGFR and ALK. The latest data on osimertinib and alectinib in the adjuvant setting. The standard of care for unresectable disease based on the PACIFIC trial and the implications of PD-L1 status. Join us for an informative discussion that unpacks the latest advancements in NSCLC treatment and emphasizes the importance of personalized care. Don't forget to subscribe for more episodes in our treatment algorithm series! #EarlyStageNSCLC, #CHECKMATE816, #NeoadjuvantTherapy, #PrecisionMedicine, #OncologyBrothers

Daz is joined by Chris and BBC Radio Lancashire's Gary Hunt for a special episode to discuss the departure of Scott Parker on the eve of the Leeds United game. Plus, the trio delve into the club's newly-published accounts and wonder whether ALK could run a chip shop! 

Joy and Patrick Tubby, who live in England, have both been passionate about lighthouses for a long time. In fact, they were engaged and married at lighthouses. Joy wrote the first edition of her book Lighthouse Accommodation Britain and Worldwide back in 1999, and the book has been updated several times. Joy is an active volunteer and Trust secretary for the Happisburgh Lighthouse, the UK's only privately operated working lighthouse. She is also an active volunteer for the Association of Lighthouse Keepers, or ALK. And she also manages an extensive website at lighthouseaccommodation.co.uk. Joy and Patrick Tubby at Skerryvore Lighthouse (lighthouseaccommodation.co.uk) Joy's husband Patrick has been chairman of the Happisburgh Lighthouse Trust for nearly 20 years, and is an active volunteer for the Friends of Happisburgh Lighthouse. He's the East Anglia regional representative for the ALK. Happisburgh Lighthouse, USLHS archives

In dieser Podcastfolge geht es um die 12 Stufen ins Burnout:    1.⁠ ⁠Zwang, sich zu beweisen  2.⁠ ⁠Immer mehr Einsatz und Stress  3.⁠ ⁠Vernachlässigung eigener Bedürfnisse    4.⁠ ⁠Verdrängen von Konflikten  5.⁠ ⁠Familie / Freunde werden zur Belastung  6.⁠ ⁠Zynismus    7.⁠ ⁠emotionaler Rückzug  8.⁠ ⁠Verhaltensänderung (Essen, Alk, etc.)  9.⁠ ⁠Gefühl von Leere   10.⁠ ⁠Sinn- und Hoffnungslosigkeit 11.⁠ ⁠Teufelskreis der Selbstabwertung 12.⁠ ⁠Kompletter Zusammembruch   Wichtig: In jeder Stufe ist eine Umkehr möglich und lieber früher als später zum Hausarzt. Bevor es klinisch wird, ergibt Stress-Coaching sehr viel Sinn - oder als Rückfall-Prophylaxe! Stress-Coach Ausbildung - Start 10. Mai 2026: www.drachenberg.de/stress-coach

Traffik - Starquake MKII - Tango Dj Sofa - Kill A Soundboy (Settle Down remix) X-E-DOS - Ode II Vinyl Junkie & Tim Reaper - Hear Me Acen - Play 2092 (Alk-e-d & Beeno Remix) Neekeetone - Watch And Move Tommy The Cat - Enter The Shogun X-E-DOS - Wake Up Neekeetone - Galya Quartz - Falling Gradients Gred Lvov, Kybel - Parallel Deathmachine - Kinetic The DJ Producer - Modus Operandi Dolphin - Northern Echoes Adamant Scream - This Breaks My Fucking Heart The DJ Producer - Paradise Is Never Deathmachine - When The Music Stops Dolphin - Buckshot Mykoz - Run Away Khaoz Engine - Uppercut The Rukkus - Bounce With Me More from Red Flag soundcloud.com/redflaghardcore

Greavsey is joined by Darren and BBC Radio Lancashire's Gary Hunt to debrief the Clarets' latest defeat.  Plus, the trio look at ALK's horrendous results record in recent months across both their clubs and make renewed calls for a director of football to sort out the transfer mess.  

Advanced practice providers discuss biomarker testing in patients with lung cancer. Listen in to learn from Beth Sandy, MSN, CRNP,FAPO, and Denise Rouse, MS, PA-C, about key biomarker testing in patients with lung cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker testing in patients with lung cancer. Presenters: Beth Sandy, MSN, CRNP, FAPO  Thoracic Oncology Nurse Practitioner Abramson Cancer Center University of Pennsylvania Philadelphia, Pennsylvania Denise Rouse, MS, PA-C  Physician Assistant Thoracic Medical Oncology Department of Medicine, Section of Hematology/Oncology The University of Chicago Medicine & Biological Sciences Chicago, Illinois Link to full program: https://bit.ly/4rt1OCl Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Burnley chairman Alan Pace's comments about "three-year olds" and "temper tantrums" have inflamed passions among Burnley fans. Former Burnley FC PR manager Ed Abis joins Bodes, Simon and Greavesy to react to the 'car crash' Football Focus interview and discuss ALK's stewardship of the club in general. Will Pace make a decision over Scott Parker's future? How can the club better organise the football side to ensure improved performances and end the chaos around the team.

Jessica Donington, MD, and Christine Bestvina, MD, join host Erin Gillaspie, MD, to unpack key lung cancer advances from ESMO 2025, including adjuvant ALK inhibition (ALINA, ELEVATE), perioperative immunotherapy (KEYNOTE-671), and the expanding neoadjuvant space in borderline resectable disease.

Dr. Hope Rugo and Dr. Vivek Subbiah discuss innovative trial designs to enable robust studies for smaller patient populations, as well as the promise of precision medicine, novel therapeutic approaches, and global partnerships to advance rare cancer research and improve patient outcomes. TRANSCRIPT  Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center [in Los Angeles]. The field of rare cancer research is rapidly transforming thanks to progress in clinical trials and treatment strategies, as well as improvements in precision medicine and next-generation sequencing that enable biomarker identification. According to the National Cancer Institute, rare cancers occur in fewer than 150 cases per million each year, but collectively, they represent a significant portion of all cancer diagnoses. And we struggle with the appropriate treatment for these rare cancers in clinical practice. Today, I am delighted to be joined by Dr. Vivek Subbiah, a medical oncologist and the chief of early-phase drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Subbiah is the lead author of a paper in the ASCO Educational Book titled "Designing Clinical Trials for Patients with Rare Cancers: Connecting the Zebras," a great title for this topic. He will be telling us about innovative trial designs to enable robust studies for small patient populations, the promise of precision medicine, and novel therapeutic approaches to improve outcomes, and how we can leverage AI now to enroll more patients with rare cancers in clinical trials. Our full disclosures are available in the transcript of this episode.  Dr. Subbiah, it is great to have you on the podcast today. Thanks so much for being here. Dr. Vivek Subbiah: Thank you so much, Dr. Rugo, and it is an honor and pleasure being here. And thank you for doing this podcast for rare cancers. Dr. Hope Rugo: Absolutely. We are excited to talk to you. And congratulations on this fantastic paper. It is such a great resource for our community to better understand what is new in the field of rare cancer research. Of course, rare cancers are complex and multifaceted diseases. And this is a huge challenge for clinical oncologists. You know, our clinics, of course, cannot be designed as we are being very uni-cancer focused to just be for one cancer that is very rare. So, oncologists have to be a jack of all trades in this area. Your paper notes that there are approximately 200 distinct types of rare and ultra-rare cancers. And, by definition, all pediatric cancers are rare cancers. Of course, clinical trials are essential for developing new treatment strategies and improving patient outcomes, and in your paper, you highlight some unique challenges in conducting trials in this rare cancer space. Can you tell us about the challenges and how really innovative trial designs, I think a key issue, are being tailored to the specific needs of patients with rare cancer and, importantly, for these trials? Dr. Vivek Subbiah: Rare cancers present a perfect storm of challenges. First, the patient populations are very small, which makes it really hard to recruit enough participants for traditional type trials. Second, these patients are often geographically dispersed across multiple cities, across multiple states, across multiple countries, across multiple zip codes. So, logistics become complicated. Third, there is often limited awareness among clinicians, which delays referrals and diagnosis. Add to that regulatory hurdles, funding constraints, and you can see why rare cancer trials are so tough to execute. To overcome these barriers, we are seeing some really creative novel trial designs. And there are four different types of trial designs that are helping with enrolling patients with rare cancers. The first one is the basket trial. So let us talk about what basket studies are. Basket studies group patients based on shared genetic biomarkers or shared genetic mutations rather than tumor type. So instead of running separate 20 to 30 to 40 trials, you can study one therapy across multiple cancers. The second type of trial is the umbrella trial. The umbrella trials flip that concept of basket studies. They focus on one cancer type but test multiple targeted therapies within it. The third category of innovative trials are the platform studies. Platform trials are another exciting innovation. They allow new treatment arms to be added or removed as the data matures and as the data evolves, making trials more adaptive and efficient. The final category are decentralized tools in traditional trials, which are helping patients participate closer to where they are so that they can sleep in their own bed, which is, I think, a game changer for accessibility.  These designs maximize efficiency and feasibility for rare cancer research and rare cancer clinical trials. Dr. Hope Rugo: I love the idea of the platform trials that are decentralized. And I know that there is a trial being worked on with ARPA-H (Advanced Research Projects Agency for Health) funding in triple-negative breast cancer as well as in lung cancer, I think, and others with this idea of a platform trial. But it is challenged, I think, by precision medicine and next-generation sequencing where some patients do not have targetable markers, or there isn't a drug to target the marker. I think those are almost the same thing. We have really seen that these precision medicine ideas and NGS have moved the needle in helping to identify genetic alterations. This helps us to be more personalized. It actually helps with platform studies to customize trial enrollment. And we hope that this will result in better outcomes. It also allows us, I think, to study drugs even in the early stage setting more effectively. How can these advances be best applied to the future of rare cancers, as well as the challenges of not finding a marker or not having a drug? Dr. Vivek Subbiah: Thank you so much for that question. I think precision medicine and next-gen sequencing, or NGS, are truly the backbone of modern precision oncology. They have transformed how we think about cancer treatment. Instead of treating based on where the tumor originated or where the tumor started, we now look at the genetic blueprint of cancer. The NGS or next-gen sequencing allows us to sequence millions of DNA fragments quickly. Twenty, 30 years ago, they said we cannot sequence a human genome. Then it took almost a decade to sequence the first human genome. Right now, we have academic centers and commercial sequencing companies that are really democratizing NGS across all sites, not just in academic centers, across all the community sites, so that NGS is now accessible. This means that we can identify these actionable alterations like picking needles in haystacks, like NTRK fusions, RET fusions, or BRAF V600E alterations, high tumor mutational burden. This might occur across not one tumor type, across several different tumor types. So for rare cancers, this is critical because some of these mutations often define the best treatment option. Here is why this matters. Personalized therapy, right? Instead of a one-size-fits-all approach, we can tailor treatment to the patient's unique molecular profile. For trial enrollment, this can definitely help because patients can join biomarker-driven trials even if their cancer type is rare or ultra-rare. NGS technology has also helped us in designing rational studies. Many times monotherapy does not work in these cancers. So we are thinking about rational combination strategies. So NGS technology is helping us. Looking ahead, I see NGS becoming routine in clinical practice, not just at major niche academic centers, but everywhere. We will see more tumor-agnostic approvals, more molecular tumor boards guiding treatment decisions in real time. And I think we are seeing an expanded biomarker setup. Previously, we used to have only a few drugs and a handful of mutations. Now with homologous recombination defects, BRCA1/2 mutation, and expanding the HRD and also immunohistochemistry, we are expanding the biomarker portfolio. So again, I personally believe that the future is precision. What I mean by precision is delivering the right drug to the right patient at the right time. And for rare cancers, this isn't just progress. It is survival. And it is maybe the only way that they can have access to these cutting-edge precision medicines. Dr. Hope Rugo: That is so important. You mentioned an important area we will get to in a moment, the tumor-agnostic therapies. But as part of talking about that, do you think that the trials should also include just standard therapies? You know, who do you give an ADC to and when with these rare cancers? Because some of them do not have biomarkers to target and it is so disappointing for patients and providers where you are trying to screen a patient for a trial or a platform trial where you have one arm with this mutation, one arm with that, and they do not qualify because they only have a p53 loss, you know? They just do not have the marker that helps them. But we see this in breast cancer all the time. And it is tough because we don't have good information on the sequencing. So I wonder, you know, just because for some of these rare cancers it is not even clear what to use when with standard treatments. And then that kind of gets into this idea of the tumor-agnostic therapies that you mentioned. There are a lot of new treatments that are being evaluated. We have seen approval of some treatments in the last few years that are tumor-agnostic and based on a biomarker. Is that the best approach as we go forward for rare cancers? And what new treatment options are most exciting to you right now? Dr. Vivek Subbiah: Tumor-agnostic therapies, really close to my heart, are real breakthrough therapies and represent a major paradigm shift in oncology. Traditionally, for the broad listeners here, we are used to thinking about designing clinical trials and therapy like where the cancer originated, breast cancer, kidney cancer, prostate cancer, lung cancer. A tumor-agnostic therapy flips that model. Instead of focusing on the organ, they target the specific genetic alteration or biomarker that drives cancer growth regardless of where the tumor started, regardless of the location of the tumor, regardless of the zip code of the tumor. So why is this so important for rare cancers? Because many rare cancers share molecular features with more common cancers. For instance, NTRK fusion might occur in pediatric sarcoma, a salivary gland tumor, or a thyroid cancer. Historically, each of these would require separate trials, which is nearly impossible, unfeasible to conduct in these ultra-rare cancers like salivary gland cancer or pediatric sarcomas. Tumor-agnostic therapies allow us to treat all those cancers with the same targeted drug if they share that biomarker. Again, we are in 2025. The first tissue-agnostic approval, the historic precedent, was in fact an immunotherapy. Pembrolizumab was approved in 2017, May 2017, as the first immunotherapy to be approved in a tumor-agnostic way for a genomic biomarker, for MSI-High and dMMR cancers. Then came the NTRK inhibitors. So today we have not one, not two, but three different NTRK inhibitors: larotrectinib, entrectinib, and repotrectinib, which show response rates of nearly more than 60 to 75% across a handful of dozens and dozens of cancer types. Then, of course, we have RET inhibitors like selpercatinib, which is approved tissue-agnostic, and pralsetinib, which also shows tissue-agnostic activity across multiple cancers. And more recently, combination therapy with a BRAF and MEK combination, dabrafenib and trametinib, received tumor-agnostic approval for all BRAF V600E tumors with the exception of colorectal cancer. And even recently, you mentioned about antibody drug conjugates. Again, I think we live in an era of antibody drug conjugates. And Enhertu, trastuzumab deruxtecan, which was used first in breast cancer, now it is approved in a histology-agnostic manner for all HER2-positive tumors defined by immunohistochemistry 3+. So again, beyond NGS, now immunohistochemistry for HER2 is also becoming a biomarker. So again, for the broad listeners here, in addition to comprehensive NGS that may allow patients to find treatment options for these rare cancers for NTRK, RET, and BRAF, immunohistochemistry for HER2 positivity is also emerging as a biomarker given that we have a new FDA approval for this. So I would say personally that these therapies are game changers because they open doors for patients who previously had no options. Instead of waiting for years for a trial in their specific cancer type, they can access a treatment based on their molecular profile. I think it is precision medicine at its finest and best. Looking ahead, the third question you asked me is what is exciting going on? I think we will see more of these approvals. My hope is that today, I think we have nine to ten approvals. My hope is that within the next 25 to 50 years, we will have at least 50 to 100 drugs approved in this space based on a biomarker, not based on a location of the tumor type. Drug targeting rare alterations like FGFR2 fusions, FGFR amplifications, ALK fusions, and even complex signatures like high tumor mutational burden. I think we will be seeing hopefully more and more drugs approved. And as sequencing becomes routine, we will identify more patients for these therapies. I think for rare cancers, this is not just innovative approach. This is essential for them to access these novel precision medicines. Dr. Hope Rugo: Yeah, that is such a good point. I do think it is critical. Interestingly in breast cancer, it hasn't been, you know, there is always like two patients in these tumor-agnostic trials, or if that. You know, I think I have seen one NTRK fusion ever. I think that highlights the importance for rare cancers. And you know, I am hoping that that will translate into some new directions for some of our rarer and impossible-to-treat subtypes of breast cancer. It is this kind of research that is really going to make a difference. But what about those people who do not have biomarkers? What if you do not fit into that? Do you think there is a possibility of trying to do treatments for rare cancers in some prospective way that would help with that? You know, it is really a huge challenge. Dr. Vivek Subbiah: Absolutely. I think, you know, you're right, usually many of these rare cancers are driven by specific biomarkers. And again, some of the pediatric salivary gland tumors or pediatric sarcomas like fibrosarcomas, they are pathognomonic with NTRK fusions. And again, given that we have a tumor-agnostic approval, now these patients have access to these therapies. And I do not think that we would have had a trial just for pediatric fibrosarcomas with NTRK fusions. So that is one way. Another way is SWOG, right? The SWOG DART [1609] had this combination dual checkpoint, it was called the DART study dual combination chemotherapy with ipi/nivo. Now here the rare cancer subtype itself becomes a biomarker and they showed activity across multiple rare cancer subtypes. They didn't require a biomarker. As long as it was a rare or ultra-rare cancer, these patients were enrolled into the SWOG DART trial and multiple arms have read out. Angiosarcoma, Kaposi sarcoma, even gestational trophoblastic disease. Again, they have shown responses in these ultra-rare, rare cancers. Sometimes they might be seeing one or two cases a whole year. And I think this SWOG effort, this cooperative group effort, really highlighted the need for such studies without biomarkers as well. Dr. Hope Rugo: That is such a fantastic example of how to try and treat patients in a collaborative way. And in the paper, you also emphasize the need for collaborative research efforts, you know, uniting resource expertise across different ways of doing research. So cooperative groups, advocacy organizations that can really help advance rare cancer research, improve access to new therapies, and I think importantly influence policy changes. I think this already happened with the agnostic approvals. Could you tell us more about that? How can we move forward with this most effectively? Dr. Vivek Subbiah: Personally, I believe that collaboration is absolutely critical and essential for rare cancer research. No single institution, no single individual, or no single state or entity can tackle these challenges alone. The patient populations are small and dispersed. So pooling resources is the only way to run these meaningful trials. Again, it is not like singing, it is like putting a huge, huge, I would say, an opera piece together. It is not a solo, vocal therapy, but rather putting a huge opera piece like Turandot. You know, you mentioned cooperative groups. Cooperative groups, as I mentioned earlier, the SWOG DART program, the ASCO [TAPUR study]. ASCO is doing a phenomenal work of the TAPUR study. Again, this ASCO TAPUR program has enrolled so many patients with rare cancers who otherwise would not have treatment options. NCI-MATCH, the global effort, right? NCI-MATCH and the ComboMATCH are great examples. They bring together hundreds of sites, thousands of clinicians to run large-scale trials that would be impossible for any individual center or institution. These trials have already changed practice. For instance, the DART demonstrated the power of immunotherapy in rare cancers and influenced NCCN guidelines. One of the arms of the NCI-MATCH study from the BRAF V600E arm contributed towards the BRAF V600E tissue-agnostic approval. So, the BRAF V600E tissue-agnostic approval was by a pooled analysis of several studies. The ROAR study, the Rare Oncology Agnostic Research study, the NCI-MATCH dataset of tumor-agnostic cohort, and another pediatric trial, and also evidence from literature and evidence of case reports. And all this pooled analysis contributed to the tissue-agnostic approval of BRAF V600E across multiple rare cancers. There are several patient advocacy organizations which are the real unsung heroes here. Groups like, for instance, we mentioned in the paper, Target Cancer Foundation, don't just raise awareness for rare cancer research, they actively connect patients to trials providing financial, emotional support, and even run their own studies like the TRACK trial. They also influence policy to make access easier. On a global scale, initiatives like DRUP in the Netherlands, the ROME study in Italy, the PCM4EU in Europe are expanding precision medicine across these borders. These collaborations accelerate research, improve trial enrollment, and ensure patients everywhere can have access to these cutting-edge therapies. Again, it is truly a team effort, right? It is a multi-stakeholder approach. Researchers, clinicians, investigators, industry, regulators, academia, patients, patient advocates, and their caregivers all working together. And it takes a village. Dr. Hope Rugo: Absolutely. I mean, what a nice response to that. And I think really exciting and it is great to see your passion about this as well. But it helps all of us, I think, getting discouraged in treating these cancers to understand what is happening moving forward. And I think it is also a fabulous opportunity for our junior colleagues as they rise up in academics to be involved in these international collaborative efforts which are further expanding. One of the things that comes up for clinical trials for patients, and I think it is highlighted with rare cancers because, as you mentioned, people are all over the place, you know, they are so rare. They are all far away. Our patients are always saying to us, "Should I go here for a phase 1 trial?" Can you talk a little bit about how we can overcome these financial and geographic burdens for the patients? You talked about having trials locally, but it is a big financial and just social burden for patients. Dr. Vivek Subbiah: Great point. Financial cost is a major barrier in rare cancer clinical trials. It is a major barrier not just in rare cancer clinical trials, but in clinical trials in general. The economics of rare cancer research are one of the toughest challenges we face. Developing a new drug is already expensive, often billions of dollars. On an average, it takes 2 billion dollars or 2.8 billion dollars according to some data from drug discovery to approval. For rare cancers, the market is tiny, which means the pharmaceutical companies have really little financial incentive to invest. That is why initiatives like the Orphan Drug Act were created to provide tax credits, grants, and market exclusivity to encourage development for rare diseases. Clinical trials themselves are expensive because the small patient populations mean longer recruitment times and higher per-patient costs. Geographic dispersion, as you mentioned, for the patients adds travel, coordination. That is why we need to think out of the box about decentralized trial infrastructure so that we can mitigate some of these expenses. Complex trial designs like basket or platform trials sometimes require sophisticated data systems and regulatory oversight. That is a challenge. And I think some of the pragmatic studies like ASCO TAPUR have overcome those challenges. Advanced technologies like next-gen sequencing and molecular profiling also add significant upfront cost to this. Funding is also limited because rare cancers receive less attention compared to common cancers. Public funding and cooperative group trials help a lot, but I think they cannot cover everything. Patient advocacy organizations sometimes step in to bridge these gaps, but sustainable financing remains a huge challenge. So, the bottom line is without financial incentives and collaborating funding models, many promising therapies for rare cancers would never make it to patients. That is why we need system-wide policy changes, global partnerships, and innovative, effective, seamless trial designs which are so critical so that they can help reduce the cost and make research feasible so that we can deliver the right drug to the right patient at the right time. Dr. Hope Rugo: There is a lot of excitement about the future integration of AI in screening. Just at the San Antonio Breast Cancer meetings, we have a number of different presentations about AI to find markers, even like HER2, and using AI where you would screen and then match patients to clinical trials. Do you have any guidance for the rare cancer community on how to leverage this technology in order to optimize patient enrollment and, I think, identification of the best treatment matches? Dr. Vivek Subbiah: I think artificial intelligence, AI, is a game-changer in the making. Right now, clinical trial is clunky. Matching patients to trial is often manual, time consuming, laborious. You need a lot of personnel to do that. AI can automate this process by analyzing genomic data, medical records, and trial eligibility criteria to find the best matches quickly, accurately, and effectively. For the community, the key is to invest in data standardization and interoperability because AI needs clean, structured data to work effectively. Dr. Hope Rugo: Thank you so much, Dr. Subbiah, for sharing these fantastic insights with us on the podcast today and for your excellent article. Dr. Vivek Subbiah: Thank you so much. Dr. Hope Rugo: We thank you, our listeners, for joining us today. You will find a link to Dr. Subbiah's Educational Book article in the transcript of this episode. And please join us again next month on By the Book for more insightful views on key issues and innovations that are shaping modern oncology.  Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Hope Rugo   @hoperugo   Dr. Vivek Subbiah @VivekSubbiah Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:       Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx   Dr. Vivek Subbiah: Consulting/Advisory Role: Loxo/Lilly, Illumina, AADI, Foundation Medicine, Relay Therapeutics, Pfizer, Roche, Bayer, Incyte, Novartis, Pheon Therapeutics, Abbvie Research Funding (Inst.): Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, Abbvie, Mutlivir, Blueprint Medicines, Loxo, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Amgen, Turningpoint Therapeutics, Relay Therapeutics Other Relationship: Medscape, Clinical Care Options

Daz is in the in the hotseat and joined by regular Pod Squad member Greavsey and former When The Ball Moves editor Martin Barnes to look at the Clarets 2-2 draw at home to Manchester United. The trio also discuss the FA Cup visit of Millwall, transfer window hopes and ALK's multi-club model...

Burnley head to Bournemouth on Saturday looking to end their run of seven straight losses and we preview the pre-Christmas game from all angles. Plus the latest on ALK and season ticket prices and more. 

Featuring perspectives from Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields, moderated by Dr Stephen "Fred" Divers, including the following topics:  Introduction (0:00) Targeted Therapy for Non-Small Cell Lung Cancer (NSCLC) — Dr Gainor, MD (5:32) Case: A woman in her mid 60s with ALK-mutant metastatic adenocarcinoma of the lung (PD-L1 TPS 70%) — Zanetta S Lamar, MD (17:59) Case: A woman in her mid 80s with EGFR exon 19-deleted adenocarcinoma of the lung with recurrence after 4 years of osimertinib — Jennifer Yannucci, MD (27:53) Case: A woman in her late 60s with HER2-mutant metastatic adenocarcinoma of the lung — Brian P Mulherin, MD (39:41) Case: A man in his early 70s with locally recurrent squamous cell carcinoma of the lung and a MET exon 14 skipping mutation — Sean Warsch, MD (46:39) Case: A woman in her early 70s with ROS1-mutant metastatic adenocarcinoma of the lung that responds to entrectinib and then to pembrolizumab/carboplatin/pemetrexed administered upon disease progression — Dr Yannucci (52:44) Nontargeted Therapy for NSCLC; Small Cell Lung Cancer — Dr Langer (58:16) Neoadjuvant, Perioperative and Adjuvant Anti-PD-1/PD-L1 Antibody-Based Approaches for Patients with Localized NSCLC — Dr Shields (1:14:14) Case: A man in his mid 60s with localized adenocarcinoma of the lung who receives neoadjuvant cisplatin/pemetrexed/pembrolizumab and achieves a pathologic complete response — Dr Mulherin (1:23:19) Case: A man in his early 60s with metastatic mixed adenosquamous NSCLC (PD-L1 TPS 50%) — Sunil Babu, MD (1:30:04) Case: A man in his late 50s diagnosed with extensive-stage small cell lung cancer who receives carboplatin/etoposide/durvalumab — Dr Warsch (1:34:07) CE information and select publications

In our new series called Perspectives on Lung Cancer, Dr. Paul Wheatley-Price sits down with two guests, both with a depth of experience in ALK+ lung cancer, which represents about 4-8% of all lung cancer cases in Canada. Dr. Cheryl Ho, medical oncologist at BC Cancer, provides her perspective as a physician treating these types of cancers in her daily practice, while Katie Hulan shares her journey as a patient diagnosed with ALK+ lung cancer in 2021, navigating the healthcare system, and her path to launching ALK Positive Canada to advocate for better awareness of this subtype of lung cancer.

Today, things begin to grow in the rice pudding. Mr. Rushworth has the hots for landscaping, Molly gets bitchcrackers for Miss Crawford, and the tides turn on our affections for Edmund when he lends out Fanny's mare. Topics discussed include hear me out cakes, apricots, Mary Crawford's poor breeding, what values we take from our families, Jane Austen's beautiful descriptions of love and how we're getting it in a different way in this book, regifting, Fanny as a chronically ill and/or anxious girlie, and pug the basset hound.Patron Study Questions this week come from Ghenet, Avi, Spring, Diana L., Angelika, Katie, Linnea, Marija, and Melissa. Topics discussed include POV shifting, landscaping and architecture, chronic illness in Austen, Edmund's manipulation of Fanny, Fanny's relationship to the servants, the number of monologues in this book, Edmund being more like his family than we thought, and all things Mary Crawford.Becca's Study Questions: Topics discussed include Edmund and Fanny's conversation about Mary and the romance brewing between Edmund and Mary.Funniest Quote: “The tree thrives well beyond a doubt, madam. The soil is good, and I never pass it without regretting that the fruit should be so little worth the trouble of gathering.”Questions moving forward: If not her cousin, then whomst?Who wins the chapters? The horse

"It's critical to identify those mutations found that are driving the cancer's growth and guide the personalized treatment based on those results. And important to remember, too, early testing is crucial for patients with non-small cell lung cancer (NSCLC). In studies, it has been found to be associated with improved survival outcomes and reduced mortality," ONS member Vicki Doctor, MS, BSN, BSW, RN, OCN®, precision medicine director at the City of Hope Atlanta, GA, Chicago, IL, and Phoenix, AZ, locations, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the oncology nurse's role in NSCLC biomarker testing. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Lilly Oncology and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities Episode 238: Cancer Genomics for Every Oncology Nurse Episode 157: Biomarker Testing Improves Outcomes for Patients With Non-Small Cell Lung Cancer ONS Voice articles: Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Only a Third of Patients With Advanced Cancer Get Biomarker Testing, Limiting Use of Potentially Effective Precision Therapies Precision Medicine in Lung Cancer: How Comprehensive Testing Optimizes Patient Outcomes Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Using Nurse Navigators to Improve Timeliness of Biomarker Testing for Non-Small Cell Lung Cancer Oncology Nursing Forum article: Precision Medicine Testing and Disparities in Health Care for Individuals With Non-Small Cell Lung Cancer: A Narrative Review Other ONS resources: Best Practices for Biomarker Testing in Non-Small Cell Lung Cancer: A Case Study Genomics and Precision Oncology Learning Library Genomics Case Study: Precision Medicine in the Setting of Metastatic Non-Small Cell Lung Cancer Biomarker Database (refine by non-small cell lung cancer) Genomic Biomarkers Huddle Card Targeted Therapy Huddle Card National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "These biomarkers are used to provide information about cancer's characteristics or behavior. In oncology precision medicine specifically, molecular tests can help with diagnosing a cancer that is maybe an unknown primary. It can help with monitoring response to therapy, detect recurrence of disease before other tests can find that, predict prognosis or how aggressive the cancer may be, and guide treatment decisions for targeted therapies." TS 3:14 "Some of the key biomarkers recommended by the National Comprehensive Cancer Network (NCCN) to be tested in patients who have NSCLC are EGFR, ALK, KRAS, BRAF, MET exon 14 skipping mutation, HER2 which is a protein expression from an ErbB protein, PD-L1 which is a protein expression that's used to guide immunotherapy choices, and then finally there are three fusions: ROS1, RET, and NTRK. [These] are pretty rare but really important to be tested for in patients who have NSCLC." TS 3:46 "Another important challenge for nurses related to this topic is that these results may not reveal a targeted mutation for the patient and that could be very disappointing. So, being able to provide that emotional support to a patient if they have that result … you can actually reinforce with them that if [they] go onto another treatment that the physician decides to put [them] on, the tumor can change. New pathogenic variants can develop based on the treatment that they're getting, and another test can be done. And maybe at that time—a new biomarker that could be targeted—we'd be seeing on the new test." TS 7:32  "Another circumstance we didn't talk about yet is that maybe the result came back saying that the quality was not sufficient. And sometimes that happens, but that doesn't mean that we're at the end of the road, necessarily. So, you could explain to the patient that that may mean that possibly, a new biopsy would be ordered by the physician. Or if a new biopsy or another tissue sample is not available, then maybe the physician would pivot to sending a blood specimen for the molecular testing. So that would definitely be a way [nurses] could support their patients." TS 11:52 "In the case of patients with NSCLC, early testing is so important. So, advocating for that prompt biomarker testing to be done, making sure that it's comprehensive, that it's actually looking for all of those—I think it was 12 biomarkers—that I mentioned earlier. That this testing is done as soon as possible after diagnosis or progression. Something that I talk about all the time—personalized care, precision medicine—really matters. So, tailoring treatments for patients based on the biology of the tumor that's driving the cancer's growth is really crucial if you're going to be working as an oncology nurse. Another crucial thing, because it's changing so quickly, is to stay informed." TS 16:23

Dans ce nouvel épisode et en ce mois de sensibilisation au cancer du poumon, Mélanie et Ginger reçoivent Manon.Manon a appris il y a un peu plus d'un an qu'elle est atteinte d'un cancer du poumon ALK+ , dit « le cancer du non-fumeur ».Manon est aussi active dans l'association ALK France Cancer Poumon https://alkros1france.com/ créée en 2021, qui regroupe patients, aidants et professionnels concernés par les cancers du poumon à mutation rare (ALK et ROS1). Elle informe et accompagne environ 400 patients, soutient la recherche et organise une collecte de fond de 105 000€.Un essai clinique innovant, baptisé EspoirALK, est prêt à démarrer à l'Institut Gustave Roussy, particulièrement prometteur pour un tiers des patients ALK. Soutenu par des experts mondiaux (Pr Besse, Dr Shaw, Pr Barlesi), cet essai pourrait redonner de l'espoir à des patients en impasse thérapeutique.Pour aider la recherche, et soutenir le lancement de cet essai clinique une cagnotte est lancée > https://www.helloasso.com/associations/alk-france-cancer-poumon/collectes/espoir-alk-1-essai-clinique-pour-la-vie Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.